Orally Active Aminopyridines as Inhibitors of Tetrameric Fructose-1,6-Bisphosphatase.
Hebeisen, P., Haap, W., Kuhn, B., Mohr, P., Wessel, H.P., Zutter, U., Kirchner, S., Ruf, A., Benz, J., Joseph, C., Alvarez-Sanchez, R., Gubler, M., Schott, B., Benardeau, A., Tozzo, E., Kitas, E.(2011) Bioorg Med Chem Lett 21: 3237
- PubMed: 21550236 
- DOI: https://doi.org/10.1016/j.bmcl.2011.04.044
- Primary Citation of Related Structures:  
2Y5K, 2Y5L - PubMed Abstract: 
A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase.
Organizational Affiliation: 
F. Hoffmann-La Roche Ltd, Discovery Research Basel, CH-4070 Basel, Switzerland.